Direct Infection

   During the Covid-19 phase trials, test subjects who received the preliminary vaccine were instructed to continue their normal daily life until the end of the trial period. They would then be examined if they had contracted the virus and determined if the experimental vaccine had a positive or negative effect compared to a non-vaccinated group of test subjects.

   The problem with this approach is that the chances of the subject being infected by the virus are entirely dependent upon coming into contact with an already infected person. Which is not a 100% guarantee.

   Especially if the general public is taking the necessary precautions against spreading the virus (e.g., face masks, keeping a proper distance, etc.). If it was determined that not enough test subjects were infected, another trial period would commence which would only further delay the urgent need for results during a viral outbreak.

   Perhaps, a better alternative would be to directly infect the test subjects with the virus itself, either by injection or spray, to ensure that the subjects were properly affected for the experimental vaccine. Direct injection would guarantee that the test subjects were infected with the virus, while a spray mist would simulate normal public conditions (but at a lower contraction rate).

   By making this simple adjustment, vaccine research may be accelerated which may be essential for a rapid response during a global pandemic.

Hospitalized Patients

   When the Covid-19 vaccine was determined that it was successful against the virus, the vaccine was administered in prioritized order (e.g., health care workers, first responders, etc.), but none was given to those who were already hospitalized with the virus.

   This practice to administer the vaccine to only healthy people could have cost some people their lives. Even though the availability of the early vaccine was limited, there were enough doses to cover both hospitalized patients and first responders at the time.

   The excuse for not providing the vaccine to hospitalized patients was that the vaccine may end up conflicting or interfering with medical treatments. However, there was no proof or evidence to support this claim. Only conjecture and the stigma that vaccines should only be administered to healthy people in order to prevent the spread of infection (and not treat it).

   A better policy moving forward would be to also include administering the early vaccine to hospitalized patients whenever possible in order to improve their chances of survival.